Skip to content
Menu

Candel Therapeutics, Inc. CADL

Full chart Compare
Set alert

Price alert · CADL

All alert types
5.13 USD -0.19 (-3.57%)

Regular-session close

5.06 -0.07 -1.36%

After hours · Nov 19, 7:52 PM ET

5.07 Day range 5.45
4.35 52-week range 14.00
YTD
-9.20%
1 year
+16.06%

5D -0.67 (-11.49%)

55.5066.50FriMonTueWedThu5.16
Market cap
402.43M
EPS (ttm)
-1.53
Shares out
76.52M
Forward P/E
-21.12
YTD return
-9.20%
1-year return
+16.06%
50-day average
10.75
200-day average
7.27
Volume
1.19M
Avg volume
1.26M
Open
5.38
Previous close
5.32
Day's range
5.07 – 5.45
52-week range
4.35 – 14.00
Beta
-0.50
Price target
21.00 (+309.4%)

Key statistics

Enterprise value
831.22M
Price / book
7.97
Free cash flow
-35.75M
Total cash
201.56M
Total debt
49.52M
Return on equity
-81.84%
Short % of float
20.94%

Fundamental scorecard

4 of 25 checks passed on CADL’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CADL Revenue — quarterly 0
CADL Net income — quarterly -21.87M
CADL EPS — quarterly -0.28

Earnings

CADL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2026Sep 30, 2026-0.30———
Aug 13, 2026Jun 30, 2026-0.23793-0.52-0.28-118.55%
May 14, 2026Mar 31, 2026-0.22-0.14+0.08+36.36%
Mar 12, 2026Dec 31, 2025-0.24-0.54-0.30-125.00%
Nov 13, 2025Sep 30, 2025-0.17-0.21-0.04-23.53%
Aug 14, 2025Jun 30, 2025-0.17-0.09+0.08+47.06%

Upgrades / downgrades

CADL analyst upgrades and downgrades
DateFirmActionFromTo
Aug 14, 2026B of A SecuritiesmainNeutralNeutral
Aug 13, 2026HC Wainwright & Co.reitBuyBuy
Jul 13, 2026Stifelinit—Buy
Apr 20, 2026Cantor Fitzgeraldinit—Overweight
Mar 18, 2026CitigroupmainBuyBuy
Mar 13, 2026CitigroupmainBuyBuy

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
candeltx.com

News

Your note

Sign in to keep a note on CADL — it syncs with the Stock Master app.

Insider holders

CADL insider holders
InsiderRelationLatest transactionDateShares held
AGUILAR-CORDOVA ESTUARDOBeneficial Owner of more than 10% of a Class of SecuritySaleOct 14, 20246,053,780
BARONE FRANCESCAOfficerSaleJun 28, 202677,362
MANNING PAUL B.DirectorPurchaseFeb 22, 20260
MARTELL CHRISTOPHERDirectorStock Award(Grant)Jun 24, 20250
NABEL GARY J.DirectorStock Award(Grant)Jun 24, 20255,353
NICHOLS WILLIAMS GARRETTOfficerSaleJul 27, 202552,493

Institution ownership

CADL institution ownership
Holder% heldSharesValueReported
FMR, LLC14.36%10,990,535145.08MJun 29, 2026
RTW Investments LP8.39%6,422,01884.77MJun 29, 2026
Blackrock Inc.6.49%4,969,04065.59MJun 29, 2026
State Street Corporation4.64%3,549,82346.86MJun 29, 2026
Acorn Capital Advisors, LLC 4.57%3,497,94846.17MJun 29, 2026
Portolan Capital Management, LLC4.56%3,490,39846.07MJun 29, 2026

Fund ownership

CADL fund ownership
Holder% heldSharesValueReported
Fidelity Select Portfolios-Select Biotechnology Portfolio6.36%4,864,75364.21MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.76%2,108,46627.83MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.65%2,024,03926.72MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.57%1,968,03425.98MMar 30, 2026
Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd.2.50%1,911,11525.23MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.16%1,650,82821.79MJun 29, 2026